BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD.

BrightGene Bio-Medical Technology Co., Ltd.

688166

CNE100003PR1

Pharmaceuticals

End-of-day quote Shanghai S.E. 21/09/2026			5-day change	1st Jan Change
36.26 ^CNY	+3.51%		+2.92%	-26.09%

08-30	BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-07	BrightGene Bio-Medical Technology Shows Positive Results in US, China Clinical Studies	MT

Bgm0504 Achieves 19.3% Robust Weight Reduction, 16.5 Cm Waist Circumference Decrease, Significant Sbp/Dbp Improvements Of 22.9/12.9 Mmhg, And 70.7 ?mol/L Uric Acid Reduction Phase Iii Trial Meets Primary Endpoint And All Key Secondary Endpoints

Published on 05/05/2026 at 04:56 pm +04

Reuters

This article is reserved for our members.

Continue with Google Continue with Apple Continue with LinkedIn

or by email

Continue with an email.

Latest news about BrightGene Bio-Medical Technology Co., Ltd.

08-30	BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-07	BrightGene Bio-Medical Technology Shows Positive Results in US, China Clinical Studies	MT
08-03	BrightGene Bio-Medical Technology Subsidiary Receives China Drug Registration Certificate for COPD Inhalation Spray; Shares Rise 5%	MT
07-27	BrightGene Gets Registration Certificate for Spray for Chronic Obstructive Pulmonary Disease	MT
05-19	BrightGene Resubmits Hong Kong IPO Application	MT
05-12	Brightgene Bio-Medical Reports Phase Iii Results for Bgm0504	CI
05-06	Participants of BrightGene's Phase 3 Trial See Trimmed Waistlines	MT
05-05	Bgm0504 Achieves 19.3% Robust Weight Reduction, 16.5 Cm Waist Circumference Decrease, Significant Sbp/Dbp Improvements Of 22.9/12.9 Mmhg, And 70.7 ?mol/L Uric Acid Reduction Phase Iii Trial Meets Primary Endpoint And All Key Secondary Endpoints	RE
05-05	Brightgene Bio-Medical Technology Co., Ltd. Announces Positive Phase III Results for Bgm0504 Injection	CI
04-29	BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-10	Declaration of Voting results by BrightGene Bio-Medical Technology	CI
04-01	BrightGene Bio-Medical Technology Receives Director Nomination from Jiandong Yuan	CI
03-25	BrightGene Bio-Medical Technology Co., Ltd. Announces Positive Topline Phase 1 Results of Oral Bgm0504 in Obesity in China and the United States	CI
03-25	BrightGene Reports Positive Phase I Results for Oral BGM0504 in Obesity	MT
03-20	BrightGene's 2025 Profit Drops 71%, Revenue Slips 5%	MT

Chart BrightGene Bio-Medical Technology Co., Ltd.

Duration

Period

Chart BrightGene Bio-Medical Technology Co., Ltd.

688166: Dynamic Chart

BrightGene Bio-Medical Technology Co Ltd is a China-based company mainly engaged in the research and development, production and sales of raw materials, pharmaceutical intermediates and preparations, as well as providing related technology transfer. The Company's products mainly cover therapeutic areas such as antiviral, antifungal, immunosuppression, respiratory system, anti-tumor and metabolism. Core products in the antiviral field include antifungal active pharmaceutical ingredients (APIs), Oseltamivir and others. The core products in the antifungal field include Caspofungin, Micafungin Sodium, Anidulafungin, Posaconazole. Core products in the immunosuppression field include Everolimus, Pimecrolimus and others. Core products in the respiratory system include Budesonide, Salmeterol, Fluticasone, and Tiotropium. Core products in the anti-tumor field include Eribulin and Lubitidin. Core products in the metabolic field include the Innovative drug BGM0504.

Employees

1,199

Sector

Pharmaceuticals

More about the company